JPMorgan analyst Eric Joseph lowered the firm’s price target on PTC Therapeutics (PTCT) to $67 from $75 and keeps an Overweight rating on the shares. The firm updated the company’s model post the Q1 report. The pullback in shares “likely creates an attractive opening for investors to get in/add to the name heading into the regulatory rich summer,” the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTCT:
- PTC Therapeutics: Strong Financial Performance and Promising Product Launches Justify Buy Rating
- PTC Therapeutics upgraded to Neutral from Sell at Citi
- PTC Therapeutics Reports Strong Q1 2025 Results
- PTC Therapeutics: Balancing Strategic Success with Regulatory Uncertainty – A Hold Rating Analysis
- PTC Therapeutics Reports Strong Q1 2025 Financial Results